Novelix Pharmaceuticals Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Net Income	0.85	0.1	-0.6	-20.27	-37.64
Depreciation & Amortization	0.38	0.38	0.56	0.8	2.09
Other Amortization	-	-	-	0.22	0.02
Loss (Gain) From Sale of Assets	-	-	-	4.57	-
Loss (Gain) From Sale of Investments	-	-	-	15	-0.1
Other Operating Activities	0.23	-2.97	-5.14	4.6	-2.62
Change in Accounts Receivable	-225.94	3.3	-16.52	22.79	50.43
Change in Inventory	3.51	-3.74	-2.89	-0.7	-0.2
Change in Accounts Payable	84.12	-0.52	0.53	-11.15	3.94
Operating Cash Flow	-136.85	-3.43	-24.05	15.86	15.93
Operating Cash Flow Growth	-	-	-	-0.42%	153.83%
Capital Expenditures	-1.06	-	-0.04	-17.98	-0.3
Sale of Property, Plant & Equipment	-	0.18	-	-	-
Investment in Securities	30.21	-1.39	22.84	15.08	-1.06
Other Investing Activities	0.16	3.07	-22.04	-4.69	2.71
Investing Cash Flow	29.3	1.86	0.75	-7.6	1.36
Long-Term Debt Repaid	-	-	-	-	-7.67
Net Debt Issued (Repaid)	-	-	-	-	-7.67
Issuance of Common Stock	30.65	-	-	-	-
Other Financing Activities	82.5	-	-	-	-
Financing Cash Flow	113.15	-	-	-	-7.67
Miscellaneous Cash Flow Adjustments	0	0	-	-0	0
Net Cash Flow	5.61	-1.57	-23.3	8.26	9.62
Free Cash Flow	-137.91	-3.43	-24.1	-2.12	15.63
Free Cash Flow Growth	-	-	-	-	199.65%
Free Cash Flow Margin	-44.87%	-7.58%	-125.49%	-2.38%	16.31%
Free Cash Flow Per Share	-14.69	-0.33	-2.98	-0.26	1.93
Levered Free Cash Flow	-159.47	4.48	10.27	-12.33	34.19
Unlevered Free Cash Flow	-159.47	4.48	10.27	-11.97	34.53
Change in Working Capital	-138.3	-0.96	-18.87	10.94	54.18

Source: S&P Global Market Intelligence. Standard template. Financial Sources.